Information Provided By: 
Fly News Breaks for November 15, 2018
BSX
Nov 15, 2018 | 09:20 EDT
Guggenheim analyst Chris Pasquale raised his price target on Boston Scientific to $45 and kept his Buy rating, saying its recent acquisitions of 8 private companies for $1.5B has positioned the company for a "best-in-class" topline growth of over 10% in 2020. The analyst notes that the revenue impact of the acquisitions adds to his bullish thesis outlined in July when he added the stock to his Best Ideas list based on his expectation of Lotus coming to market and its non-TAVR pipeline being "underappreciated" by the Street.
News For BSX From the Last 2 Days
BSX
Apr 23, 2024 | 13:18 EDT
